Exscientia (EXAI) Stock Forecast, Price Target & Predictions
EXAI Stock Forecast
Exscientia stock forecast is as follows: an average price target of $5.00 (represents a -0.20% downside from EXAI’s last price of $5.01) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.
EXAI Price Target
The average price target for Exscientia (EXAI) is $5.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential -0.20% downside from EXAI's last price of $5.01.
EXAI Analyst Ratings
According to 2 Wall Street analysts, Exscientia's rating consensus is 'Hold'. The analyst rating breakdown for EXAI stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Exscientia Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Peter Lawson | Barclays | $5.00 | $4.77 | 4.89% | -0.20% |
The latest Exscientia stock forecast, released on Aug 13, 2024 by Peter Lawson from Barclays, set a price target of $5.00, which represents a 4.89% increase from the stock price at the time of the forecast ($4.77), and a -0.20% decrease from EXAI last price ($5.01).
Exscientia Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $5.00 | $5.00 |
| Last Closing Price | $5.01 | $5.01 | $5.01 |
| Upside/Downside | -100.00% | -0.20% | -0.20% |
In the current month, the average price target of Exscientia stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Exscientia's last price of $5.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Barclays | Overweight | Equal-Weight | Downgrade |
| Aug 08, 2024 | Cowen & Co. | Buy | Hold | Downgrade |
| Jul 09, 2024 | Cowen & Co. | - | Buy | Initialise |
| Nov 16, 2022 | Barclays | Overweight | Overweight | Hold |
Exscientia's last stock rating was published by Barclays on Aug 13, 2024. The company Downgrade its EXAI rating from "Overweight" to "Equal-Weight".
Exscientia Financial Forecast
Exscientia Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $5.76M | $8.20M | $7.03M | $8.66M | $9.16M | $4.14M | $17.64M |
| Avg Forecast | $26.17M | $24.67M | $12.59M | $8.07M | $13.24M | $4.48M | $6.62M | $7.23M | $6.11M | $21.09M | $39.01M | $24.47M | $7.50M | $13.17M |
| High Forecast | $26.17M | $24.67M | $12.59M | $8.07M | $13.24M | $4.54M | $6.62M | $7.23M | $6.11M | $21.09M | $39.01M | $24.47M | $7.50M | $13.17M |
| Low Forecast | $26.17M | $24.67M | $12.59M | $8.07M | $13.24M | $4.43M | $6.62M | $7.23M | $6.11M | $21.09M | $39.01M | $24.47M | $7.50M | $13.17M |
| # Analysts | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 0.80% | 1.34% | 0.33% | 0.22% | 0.37% | 0.55% | 1.34% |
Exscientia's average Quarter revenue forecast for Jun 23 based on 1 analysts is $6.62M, with a low forecast of $6.62M, and a high forecast of $6.62M. EXAI's average Quarter revenue forecast represents a 14.94% increase compared to the company's last Quarter revenue of $5.76M (Mar 23).
Exscientia EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-38.18M | $-46.70M | $-49.72M | $-52.41M | $-34.94M | $-21.11M | $-5.51M |
| Avg Forecast | $-24.75M | $-23.33M | $-11.90M | $-7.64M | $-12.53M | $-4.24M | $-6.26M | $-6.83M | $-5.78M | $-19.95M | $-36.90M | $-23.14M | $-7.10M | $-12.45M |
| High Forecast | $-24.75M | $-23.33M | $-11.90M | $-7.64M | $-12.53M | $-4.19M | $-6.26M | $-6.83M | $-5.78M | $-19.95M | $-36.90M | $-23.14M | $-7.10M | $-12.45M |
| Low Forecast | $-24.75M | $-23.33M | $-11.91M | $-7.64M | $-12.53M | $-4.29M | $-6.26M | $-6.83M | $-5.78M | $-19.95M | $-36.90M | $-23.14M | $-7.10M | $-12.45M |
| Surprise % | - | - | - | - | - | - | - | 5.59% | 8.08% | 2.49% | 1.42% | 1.51% | 2.97% | 0.44% |
undefined analysts predict EXAI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Exscientia's previous annual EBITDA (undefined) of $NaN.
Exscientia Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-37.64M | $-47.10M | $-39.62M | $-34.78M | $-20.35M | $-20.08M | $-5.08M |
| Avg Forecast | $-18.51M | $-20.04M | $-23.94M | $-37.79M | $-34.50M | $-42.02M | $-41.38M | $-42.12M | $-38.19M | $-33.51M | $-19.62M | $-16.89M | $-11.38M | $-15.42M |
| High Forecast | $-18.51M | $-18.70M | $-23.94M | $-37.79M | $-29.01M | $-42.02M | $-41.38M | $-42.12M | $-38.19M | $-33.51M | $-19.62M | $-16.89M | $-11.38M | $-15.42M |
| Low Forecast | $-18.51M | $-20.71M | $-23.94M | $-37.79M | $-39.98M | $-42.02M | $-41.38M | $-42.12M | $-38.19M | $-33.51M | $-19.62M | $-16.89M | $-11.38M | $-15.42M |
| Surprise % | - | - | - | - | - | - | - | 0.89% | 1.23% | 1.18% | 1.77% | 1.20% | 1.77% | 0.33% |
Exscientia's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EXAI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Exscientia SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $10.91M | $9.90M | $11.51M | $14.63M | $10.27M | $6.38M | $8.60M |
| Avg Forecast | $31.06M | $29.28M | $14.94M | $9.58M | $15.72M | $5.32M | $7.86M | $8.58M | $7.25M | $25.03M | $46.31M | $29.04M | $8.91M | $15.63M |
| High Forecast | $31.06M | $29.28M | $14.94M | $9.58M | $15.72M | $5.38M | $7.86M | $8.58M | $7.25M | $25.03M | $46.31M | $29.04M | $8.91M | $15.63M |
| Low Forecast | $31.06M | $29.28M | $14.94M | $9.58M | $15.72M | $5.26M | $7.86M | $8.58M | $7.25M | $25.03M | $46.31M | $29.04M | $8.91M | $15.63M |
| Surprise % | - | - | - | - | - | - | - | 1.27% | 1.37% | 0.46% | 0.32% | 0.35% | 0.72% | 0.55% |
Exscientia's average Quarter SG&A projection for Jun 23 is $7.86M, based on 1 Wall Street analysts, with a range of $7.86M to $7.86M. The forecast indicates a -27.98% fall compared to EXAI last annual SG&A of $10.91M (Mar 23).
Exscientia EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.31 | $-0.38 | $-0.32 | $-0.29 | $-0.17 | $-0.17 | $-0.04 |
| Avg Forecast | $-0.15 | $-0.16 | $-0.19 | $-0.30 | $-0.27 | $-0.33 | $-0.33 | $-0.33 | $-0.30 | $-0.26 | $-0.15 | $-0.13 | $-0.09 | $-0.12 |
| High Forecast | $-0.15 | $-0.15 | $-0.19 | $-0.30 | $-0.23 | $-0.33 | $-0.33 | $-0.33 | $-0.30 | $-0.26 | $-0.15 | $-0.13 | $-0.09 | $-0.12 |
| Low Forecast | $-0.15 | $-0.16 | $-0.19 | $-0.30 | $-0.32 | $-0.33 | $-0.33 | $-0.33 | $-0.30 | $-0.26 | $-0.15 | $-0.13 | $-0.09 | $-0.12 |
| Surprise % | - | - | - | - | - | - | - | 0.93% | 1.26% | 1.21% | 1.87% | 1.27% | 1.89% | 0.35% |
According to undefined Wall Street analysts, Exscientia's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EXAI previous annual EPS of $NaN (undefined).
Exscientia Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| UBX | Unity Bio | $1.26 | $80.00 | 6249.21% | Buy |
| ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| ADAP | Adaptimmune Therapeutics | $0.83 | $2.83 | 240.96% | Buy |
| RLAY | Relay Therapeutics | $5.85 | $19.40 | 231.62% | Buy |
| SANA | Sana Bio | $3.76 | $12.00 | 219.15% | Buy |
| PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
| AVIR | Atea Pharmaceuticals | $3.35 | $6.88 | 105.37% | Hold |
| MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
| LPTX | Leap Therapeutics | $3.67 | $5.50 | 49.86% | Buy |
| RXRX | Recursion Pharmaceuticals | $6.64 | $9.67 | 45.63% | Hold |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| ZURA | Zura Bio | $4.37 | $5.00 | 14.42% | Buy |
| KYMR | Kymera Therapeutics | $47.07 | $51.50 | 9.41% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| EXAI | Exscientia | $5.01 | $5.00 | -0.20% | Hold |
EXAI Forecast FAQ
Is Exscientia a good buy?
No, according to 2 Wall Street analysts, Exscientia (EXAI) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of EXAI's total ratings.
What is EXAI's price target?
Exscientia (EXAI) average price target is $5 with a range of $5 to $5, implying a -0.20% from its last price of $5.01. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Exscientia stock go up soon?
According to Wall Street analysts' prediction for EXAI stock, the company can go down by -0.20% (from the last price of $5.01 to the average price target of $5), down by -0.20% based on the highest stock price target, and down by -0.20% based on the lowest stock price target.
Can Exscientia stock reach $8?
EXAI's average twelve months analyst stock price target of $5 does not support the claim that Exscientia can reach $8 in the near future.
What are Exscientia's analysts' financial forecasts?
Exscientia's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $31.57M (high $31.62M, low $31.52M), average EBITDA is $-29.866M (high $-29.818M, low $-29.915M), average net income is $-160M (high $-155M, low $-166M), average SG&A $37.48M (high $37.54M, low $37.42M), and average EPS is $-1.264 (high $-1.221, low $-1.307). EXAI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $71.49M (high $71.49M, low $71.49M), average EBITDA is $-67.626M (high $-67.626M, low $-67.626M), average net income is $-100M (high $-98.945M, low $-101M), average SG&A $84.86M (high $84.86M, low $84.86M), and average EPS is $-0.792 (high $-0.782, low $-0.797).
Did the EXAI's actual financial results beat the analysts' financial forecasts?
Based on Exscientia's last annual report (Dec 2022), the company's revenue was $32.9M, which missed the average analysts forecast of $90.67M by -63.71%. Apple's EBITDA was $-229M, beating the average prediction of $-85.771M by 167.46%. The company's net income was $-143M, beating the average estimation of $-108M by 32.32%. Apple's SG&A was $46.4M, missing the average forecast of $107.63M by -56.89%. Lastly, the company's EPS was $-1.17, beating the average prediction of $-0.855 by 36.87%. In terms of the last quarterly report (Mar 2023), Exscientia's revenue was $5.76M, missing the average analysts' forecast of $7.23M by -20.27%. The company's EBITDA was $-38.178M, beating the average prediction of $-6.835M by 458.59%. Exscientia's net income was $-37.643M, missing the average estimation of $-42.124M by -10.64%. The company's SG&A was $10.91M, beating the average forecast of $8.58M by 27.26%. Lastly, the company's EPS was $-0.31, missing the average prediction of $-0.333 by -6.84%